20/20 Onsite

Home
United States
Boston, MA
20/20 Onsite

20/20 Onsite delivers comprehensive eye exams to businesses via a state-of-art mobile vision center.

20/20 Onsite (also known as 2020 Onsite) is the only provider solely dedicated to point-of-need eye assessments for clinical trials, proven to meet screening timelines, improve retention rates, and fast-track trials. This is a great way for companies to offer a unique, low-cost benefit to employees.

04/23/2026

Most booths at ARVO will show you a slide or walk you through a simulation. Booth #8083 will show you the clinic.

Step inside our Mobile Vision Clinic at ARVO 2026 and see:
• How a fully calibrated ophthalmic setup travels to a patient, not the other way around
• How we maintain equipment standards that hold up at the read center
• How one call to 20/20 Onsite manages protocol through data acquisition, without a single handoff gap
• How one accountable partner owns ocular endpoint ex*****on from protocol through acquisition, across every site

You don't need to imagine how this works in your trial. You can stand inside the vehicle that runs it.
Private tours. Limited availability. On-site in Denver.

This is the one thing you can't see on our website.
It is a working clinic. Come see the difference.

Book your tour at ARVO 2026 → https://hubs.ly/Q04cKc2Y0
Booth #8083 | May 3–7 | Denver, CO

04/18/2026

The conversations that shape ophthalmic clinical research, ex*****on models, regulatory expectations; they happen in Denver this May.

Our team will be there. Our Mobile Vision Clinic will be there. We’re scheduling a limited number of private MVC tours per day to maintain a controlled, high-quality walkthrough. And the calendar is filling up faster than you'd think.

If you want a private MVC tour or a one-on-one with our team, book now. Don't leave it to the week before.

May 3–7 | Denver, CO | Booth #8083
https://hubs.ly/Q04bLcxh0

04/17/2026

Inflammation in the eye can blur vision for months, or years.

Uveitic macular edema is a leading cause of vision loss in chronic uveitis, and new steroid-sparing immunotherapies and long-acting implants are finally showing promise.

But these trials depend on repeated OCT imaging and inflammation assessments over time, creating a heavy burden for patients already managing chronic disease.

That's where 20/20 Onsite makes the difference.

20/20 Onsite enables sponsors to run complex uveitis studies without overwhelming participants:

Mobile OCT for macular thickness monitoring
Visual acuity and contrast sensitivity testing
Anterior chamber inflammation grading
Consistent follow-up without travel barriers

We've helped sponsors reach diverse populations across 45+ ophthalmic trials while maintaining 98% data accuracy and just 9% dropout rates.

When inflammation threatens sight, consistency in care, and data is everything.

Learn more: https://hubs.ly/Q04bNs950

04/16/2026

Fenway + clinical trials isn’t a combo you see every day… but here we are.

Yesterday we were at the CORE Symposium 2026 - Fenway Park. As a Boston-based company, we think it's pretty epic that our logo is up on the big screen at Fenway Park.

Not a bad place to show up.

It was great connecting with clin ops leaders who are passionate about solving the hard problems to improve our clinical trials.

Stay tuned for some takeaways!

04/14/2026

At ARVO 2026, you’ll meet some of the team behind 20/20 Onsite at Booth #8083:

Sonali Bloom, CEO
Jessica McKenzie, VP, Life Sciences
Adam Merola, Senior Director, Life Sciences
Katie Sigg, Account Executive, Life Sciences
Queenly Berko, Business Development Representative, Life Sciences
Dr. Michelle Sandler, Optometrist

Stop by for a real conversation, get your questions answered, and see how we support ocular endpoint trials from planning through ex*****on.

Meet the team and book your tour → https://hubs.ly/Q04bGL4j0

Booth #8083 | May 3–7 | Denver, CO

04/10/2026

The most expensive line item in your ophthalmic trial isn't the equipment. It isn't site fees.

It’s what breaks when ex*****on fails.

The protocol deviation you don’t catch until Month 6.
The endpoint flagged by the read center.
The site that can’t retain a certified optometrist past Visit 3.
The enrollment gap because participants can’t access the clinic.

These don’t slow trials down.
They derail them.

At ARVO this year, we're bringing the Mobile Vision Clinic to Booth #8083 so you can see what single-call accountability actually looks like not as a concept, but as a clinic you can walk through.
One call. Certified staff. Calibrated equipment. Point-of-need.

If you're a sponsor or CRO running ocular endpoints, this tour is for you. Private sessions.
Limited slots. Book yours → https://hubs.ly/Q04bdT1B0

ARVO 2026 | Booth #8083 | Denver, May 3–7

04/08/2026

Last year, hundreds of people came to our booth at ARVO and asked the same thing: “Where’s the Mobile Vision Clinic?”

It wasn’t there.
It was deployed across active clinical trials, supporting participants nationwide.

This May, that changes.

The Mobile Vision Clinic will be on-site at ARVO 2026, Booth #8083 in Denver.

Step inside.
Walk the workflow.
See exactly how point-of-need ophthalmic assessments are executed in real trials, with calibrated equipment, certified staff, and protocol-ready operations.

Not in a virtual tour.
In the actual clinic.

Most sponsors and CROs never see the infrastructure behind their ocular endpoints until it’s already deployed.

You will.

Private tours are limited and fill quickly.
Lock in your time now → https://hubs.ly/Q049Tgv10

Booth #8083 | May 3–7 | Denver, CO

04/07/2026

1 billion people are living with vision impairment that could have been prevented or treated.

The treatments exist. The technology exists. The clinicians exist.

What's missing is someone who comes to them.

That's why we built the Mobile Vision Clinic. For the patient whose visit window closes in 48 hours and can't drive.

Health for all isn't a theme. It's an operational standard.

One call. Point-of-need.
https://hubs.ly/Q049vwT40

04/06/2026

Two out of three blind people in the world are women.

Not because the disease is different. Because the exam never happened.

This Women's Eye Health & Safety Month, awareness isn't the gap. Access is.

At 20/20 Onsite, the clinic comes directly to trial participants. Not the other way around.

One call. Point-of-need. Protocol to participant.
https://hubs.ly/Q049vBPC0

04/03/2026

Protocol deviations are rarely random.

Across ophthalmic trials, the same challenges appear repeatedly: access barriers, equipment constraints, and visit burden that erodes retention over time.

The difference between reactive correction and proactive prevention is visibility before enrollment.

20/20 Onsite supports protocol planning with experience grounded in 100,000+ ophthalmic assessments, helping sponsors:
Identify access risks before site activation
Align visit schedules with real-world participant constraints
Design delivery models that protect endpoints from the start
Prevention does not happen during ex*****on.

It happens during design.
https://hubs.ly/Q048SgVw0

04/02/2026

When the cornea swells, clarity disappears.

Fuchs' dystrophy and corneal edema are finally seeing alternatives to transplant; novel endothelial therapies and edema-reducing drugs are shifting pharmacologic treatments.

These trials require precise, serial imaging, including slit-lamp photography, corneal pachymetry, anterior segment OCT, and endothelial cell counts through specular microscopy.

20/20 Onsite brings the imaging to them. Our mobile clinics are equipped with:
Portable slit-lamp systems for detailed anterior segment imaging
Corneal thickness measurements through endothelial cell counts (pachymetry)
Standardized protocols for reproducible data

We've helped sponsors reach underserved and geographically dispersed populations, improving both diversity and retention in corneal disease trials.

When your trial is pioneering the future of corneal care, participant access can't be an afterthought.

Let's bring your corneal study to the people who need it most: https://hubs.ly/Q048SffB0

03/30/2026

When the optic nerve is under attack, vision loss can happen fast.

Optic neuritis, often the first sign of MS, causes sudden vision loss and requires immediate assessment. For patients with MS, optic neuritis is frequently the first clinical manifestation of the disease.

Further, neuro-ophthalmic studies require fast-access to visual function tests, OCT imaging, color vision testing, perimetry (visual field testing), pupillary testing (assess for RAPD), and consistent follow-ups during acute episodes. When patients are experiencing vision loss, traveling to distant sites can be overwhelming.

20/20 Onsite delivers these critical assessments at the point of need:
Rapid visual acuity and contrast sensitivity testing
Mobile OCT for retinal nerve fiber layer analysis
Consistent data collection during critical windows
Reduced dropout in longitudinal MS-related studies

We help sponsors capture the complete picture of neuro-ophthalmic disease progression without burdening participants during their most vulnerable moments.

When the optic nerve is inflamed and vision is threatened, accessibility isn't optional.

Address

Boston, MA
02110

Website

http://www.2020onsite.com/

Alerts

Be the first to know and let us send you an email when 20/20 Onsite posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to 20/20 Onsite:

Shortcuts

Want your practice to be the top-listed Clinic in Boston?